Treatment of PD‐1−/− mice with amodiaquine and anti‐CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Hepatology

• Publication date

  2015-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/hep.27549PMID 25283142
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of a novel mouse model of amodiaquine-induced liver injury with a delayed onset

  2015cited by this paper
• Isoniazid-induced liver injury and immune response in mice

  2014cited by this paper
• Idiosyncratic Adverse Drug Reactions: Current Concepts

  2013cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Using genome-wide association studies to identify genes important in serious adverse drug reactions.

  2012influential reference
• Direct Oxidation and Covalent Binding of Isoniazid to Rodent Liver and Human Hepatic Microsomes: Humans Are More Like Mice than Rats

  2012cited by this paper
• Animal models of idiosyncratic drug reactions.

  2012cited by this paper
• Hepatocyte entry leads to degradation of autoreactive CD8 T cells

  2011cited by this paper
• A Fresh Look at the Mechanism of Isoniazid‐Induced Hepatotoxicity

  2011cited by this paper
• Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH)

  2011cited by this paper
• Cbl-b and itch: key regulators of peripheral T-cell tolerance.

  2010cited by this paper
• OC-035 Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a diagnostic test accuracy meta-analysis

  2010cited by this paper
• HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

  2009cited by this paper
• Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis

  2008cited by this paper
• Hy's law: predicting serious hepatotoxicity

  2006influential reference
• Idiosyncratic Liver Injury: Challenges and Approaches

  2005cited by this paper
• Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States

  2002cited by this paper
• The liver as a site of T‐cell apoptosis: graveyard, or killing field?

  2000cited by this paper
• Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses.

  1998cited by this paper
• Amodiaquine-induced hepatitis. A report of seven cases.

  1986cited by this paper
• Amodiaquine induced agranulocytosis and liver damage.

  1986cited by this paper
• Amodiaquine-lnduced Hepatitis: A Report of Seven Cases

  1986cited by this paper

• Relevance of Reactive Metabolites and Covalent Binding to Drug Candidate Selection.

  2026cites this paper
• Mechanism of vildagliptin-induced liver injury: An idiosyncratic drug reaction mediated by inflammasome activation.

  2026cites this paper
• Single-cell transcriptomics unveils the immunologic landscape of anti-PD-1-associated indirect drug-induced liver injury.

  2026cites this paper
• Gypenoside XLIX Alleviates Diclofenac‐Induced Hepatotoxicity via Modulating Akt/NLRP3 Pathway

  2026cites this paper
• A well-characterized mechanistic model for exploring known or hypothesized T cell mediated drug induced liver injury: current capabilities and challenges for future predictivity

  2025cites this paper
• Decoding fatal toxic effects in checkpoint inhibitor therapy using real‐world pharmacovigilance data and machine learning

  2025cites this paper
• DILI prediction in drug development: present and future

  2025cites this paper
• Transcriptomic and proteomic characterization of cell and protein biomarkers of checkpoint inhibitor-induced liver injury

  2025cites this paper
• The use of PD-1 functional knockout rats to study idiosyncratic adverse reactions to nevirapine.

  2024cites this paper
• Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management

  2024cites this paper
• Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events

  2024cites this paper
• Dietary Supplement-Induced Hepatotoxicity: A Clinical Perspective

  2024cites this paper
• The development and characterization of a CRISPR/Cas9-mediated PD-1 functional knockout rat as a tool to study idiosyncratic drug reactions.

  2024influential citation
• Elucidating the Mechanisms Underlying Interindividual Differences in the Onset of Adverse Drug Reactions.

  2024cites this paper
• Protein Haptenation and Its Role in Allergy

  2024cites this paper
• Immunological Drug–Drug Interactions Affect the Efficacy and Safety of Immune Checkpoint Inhibitor Therapies

  2024cites this paper
• Development of mouse models with restricted HLA-B*57:01 presentation for the study of flucloxacillin-driven T-cell activation and tolerance in liver injury

  2023cites this paper
• Immunophenotyping to improve the mechanistic understanding of idiosyncratic drug-induced liver injury: clinical implications and future directions

  2023cites this paper
• Transgenic murine models for the study of drug hypersensitivity reactions linked to HLA-I molecules

  2023cites this paper
• What’s been Hapten-ing over the last 88 years?

  2023cites this paper
• Idiosyncratic Drug-Induced Liver Injury: From Pathogenesis to Risk Reduction

  2023cites this paper
• Stocking the toolbox—Using preclinical models to understand the development and treatment of immune checkpoint inhibitor‐induced immune‐related adverse events

  2023cites this paper
• Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitis

  2023influential citation
• Hepatotoxicity in immune checkpoint inhibitors: A pharmacovigilance study from 2014–2021

  2023cites this paper
• Clinical correlation between serum cytokines and the susceptibility to Polygonum multiflorum-induced liver injury and an experimental study.

  2022cites this paper
• Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology

  2022cites this paper
• Biochemical mechanisms of drug toxicity

  2022cites this paper
• Pathology of drug hypersensitivity reactions and mechanisms of immune tolerance

  2022cites this paper
• Does immune checkpoint inhibitor therapy increase the frequency of adverse reactions to concomitant medications?

  2022cites this paper
• The Role of Myeloid Cells in Hepatotoxicity Related to Cancer Immunotherapy

  2022cites this paper
• Mouse Models of Liver Parenchyma Injuries and Regeneration

  2022cites this paper
• Genome‐wide meta‐analysis identifies susceptibility loci for autoimmune hepatitis type 1

  2022cites this paper
• Roles of Cofactors in Drug-Induced Liver Injury: Drug Metabolism and Beyond

  2022cites this paper
• Special Section on Drug Metabolism in Liver Injury and Repair — Minireview Roles of Cofactors in Drug-Induced Liver Injury: Drug Metabolism and Beyond

  2022cites this paper
• Practical Implementation of Genetics: New Concepts in Immunogenomics to Predict, Prevent, and Diagnose Drug Hypersensitivity.

  2022cites this paper
• Trovafloxacin drives inflammation-associated drug-induced adverse hepatic reaction through changing macrophage polarization.

  2022cites this paper
• Advances in Our Understanding of the Interaction of Drugs with T-cells: Implications for the Discovery of Biomarkers in Severe Cutaneous Drug Reactions.

  2022cites this paper
• Hepatotoxicity due to herbal dietary supplements: Past, present and the future.

  2022cites this paper
• Investigating the Mechanism of Trimethoprim-Induced Skin Rash and Liver Injury

  2021cites this paper
• Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction

  2021cites this paper
• Preclinical models of acute liver failure: a comprehensive review

  2021cites this paper
• Models of Drug Induced Liver Injury (DILI)-Current Issues and Future Perspectives

  2021cites this paper
• Screening for Susceptibility-Related Biomarkers of Diclofenac-Induced Liver Injury in Rats Using Metabolomics

  2021cites this paper
• T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab

  2021cites this paper
• Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models

  2021influential citation
• Bavachin enhances NLRP3 inflammasome activation induced by ATP or nigericin and causes idiosyncratic hepatotoxicity

  2021cites this paper
• Idiosyncratic Drug-Induced Liver Injury: Mechanistic and Clinical Challenges

  2021cites this paper
• Chronic Drug-Induced Liver Injury: Updates and Future Challenges

  2021cites this paper
• Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis.

  2021cites this paper
• Testing Possible Risk Factors for Idiosyncratic Drug-Induced Liver Injury Using an Amodiaquine Mouse Model and Co-treatment with 1-Methyl-d-Tryptophan or Acetaminophen

  2021cites this paper
• The Roles of Immunoregulatory Networks in Severe Drug Hypersensitivity

  2021cites this paper
• Liver Injury Caused by Green Tea Extract in PD-1-/- Mice: An Impaired Immune Tolerance Model for Idiosyncratic Drug-Induced Liver Injury.

  2021cites this paper
• Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity

  2021cites this paper
• Mechanisms of immune checkpoint inhibitor-mediated liver injury

  2021cites this paper
• Regulation of the immune tolerance system determines the susceptibility to HLA-mediated abacavir-induced skin toxicity

  2021cites this paper
• Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect

  2020cites this paper
• What have we learned from animal models of idiosyncratic, drug-induced liver injury?

  2020influential citation
• Mechanistic mathematical representation of CD8+ T cell mediated drug-induced liver injury (DILI) Part 2: translation from experimental antigen, ovalbumin (OVA), to drug, amodiaquine (AQ) response

  2020cites this paper
• The hepatotoxicity of Polygonum multiflorum: The emerging role of the immune-mediated liver injury

  2020cites this paper
• Drug‐Induced Liver Injury

  2020cites this paper
• Application of a Rat Liver Drug Bioactivation Transcriptional Response Assay Early in Drug Development That Informs Chemically Reactive Metabolite Formation and Potential for Drug-induced Liver Injury

  2020cites this paper
• HLA transgenic mice: application in reproducing idiosyncratic drug toxicity

  2020cites this paper
• Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues

  2020cites this paper
• Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver Injury.

  2020cites this paper
• T-cell activation by low molecular weight drugs and factors that influence susceptibility to drug hypersensitivity.

  2020cites this paper
• Definition of the Chemical and Immunological Signals Involved in Drug-induced Liver Injury.

  2020cites this paper
• Acute Exacerbation of Chronic Hepatitis B: Volume 1. Definition, Research Technology, Virology, Genetics and Immunology

  2019cites this paper
• Involvement of CCL2/CCR2 macrophage recruitment in amodiaquine-induced liver injury

  2019cites this paper
• Drug-induced liver injury

  2019cites this paper
• Acute Exacerbation of Chronic Hepatitis B: Volume 2. Diagnosis and Management

  2019cites this paper
• Mechanisms of idiosyncratic drug-induced liver injury.

  2019cites this paper
• Drug-Induced Liver Disease: Mechanism and Diagnosis

  2019cites this paper
• Animal models of drug-induced liver injury.

  2019cites this paper
• Hepatocyte-Derived Exosomes Promote Liver Immune Tolerance: Possible Implications for Idiosyncratic Drug-Induced Liver Injury.

  2019influential citation
• Treatment of AECHB and Severe Hepatitis (Liver Failure)

  2019cites this paper
• Rotenone Increases Isoniazid Toxicity but Does Not Cause Significant Liver Injury: Implications for the Hypothesis that Inhibition of the Mitochondrial Electron Transport Chain Is a Common Mechanism of Idiosyncratic Drug-Induced Liver Injury.

  2019cites this paper
• Cell death in drug-induced liver injury.

  2019cites this paper
• Mechanistic Studies of Idiosyncratic DILI: Clinical Implications

  2019cites this paper
• Identification of Candidate Risk Factor Genes for Human Idelalisib Toxicity Using a Collaborative Cross Approach.

  2019cites this paper
• Risk profiling using metabolomic characteristics for susceptible individuals of drug-induced liver injury caused by Polygonum multiflorum

  2019cites this paper
• Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors

  2019cites this paper
• Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice

  2019cites this paper
• Carbamazepine promotes specific stimuli-induced NLRP3 inflammasome activation and causes idiosyncratic liver injury in mice

  2019cites this paper
• Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models

  2019cites this paper
• Immune dysregulation increases the incidence of delayed‐type drug hypersensitivity reactions

  2019cites this paper
• Hepatic macrophages in drug-induced liver injury

  2019cites this paper
• Icariside I specifically facilitates ATP or nigericin-induced NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity

  2019cites this paper
• The skin as a metabolic and immune-competent organ: Implications for drug-induced skin rash

  2018cites this paper
• Do In Vitro Assays Predict Drug Candidate Idiosyncratic Drug-Induced Liver Injury Risk?

  2018cites this paper
• Mechanisms of Inflammatory Liver Injury and Drug-Induced Hepatotoxicity

  2018cites this paper
• The Effects of Immune Modulators on Amodiaquine-Induced Liver Injury.

  2018cites this paper
• Host Risk Modifiers in Idiosyncratic Drug-Induced Liver Injury (DILI) and Its Interplay with Drug Properties

  2018cites this paper
• Models of Drug Induced Liver Injury (DILI) – Current Issues and Future Perspectives

  2018cites this paper
• Drug-Induced Liver Toxicity

  2018cites this paper
• Editor’s Highlight: An Impaired Immune Tolerance Animal Model Distinguishes the Potential of Troglitazone/Pioglitazone and Tolcapone/Entacapone to Cause IDILI

  2018cites this paper
• Immune Mechanisms in Drug-Induced Liver Injury

  2018cites this paper
• An Animal Model of Abacavir-Induced HLA-Mediated Liver Injury

  2018cites this paper
• Use of an animal model to test whether non-alcoholic fatty liver disease increases the risk of idiosyncratic drug-induced liver injury

  2018cites this paper
• Cellular and Molecular Mechanisms of Autoimmune Hepatitis.

  2018cites this paper
• Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents

  2018cites this paper